Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB says further brivaracetam analyses needed

UCB says further brivaracetam analyses needed

29th April 2009

UCB has noted further investigations are needed to fully understand the potential of brivaracetam.

Dr Iris Low-Friedrich, chief medical officer of the firm, made this comment after the company achieved promising results from two phase III trials of the drug as a treatment of partial-onset seizures in adults with epilepsy.

Upon first analysis of the data, the efficacy of the medication seems to vary between different patient subpopulations, he explained, adding the primary and secondary endpoints of the studies must be examined to gain a better understanding.

“We need to complete our review of all relevant data and will decide our next steps to bring brivaracetam to patients, after consulting with regulatory authorities,” said Dr Low-Friedrich.

Last month, UCB released its full-year fiscal results for 2008 and Roch Doliveux, chief executive officer of the business, remarked the firm had completed 12 months of “significant execution”.

He added the company continues to transform into a specialist biopharma group, concentrating on developing treatments for severe diseases of the central nervous systems and immunology.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.